María
Díez Campelo
Profesora Asociada CC. Salud
![Foto de Joan](/img/nophoto.png)
Joan
Bargay Lleonart
Joan Bargay Lleonart-rekin lankidetzan egindako argitalpenak (8)
2024
2023
-
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice
Leukemia and Lymphoma, Vol. 64, Núm. 3, pp. 679-690
2018
-
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359
2017
-
Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study
International Journal of Molecular Sciences, Vol. 18, Núm. 4
2015
-
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
Leukemia Research, Vol. 39, Núm. 3, pp. 296-306
-
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study
The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266
2014
-
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201
-
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis
Leukemia Research, Vol. 38, Núm. 3, pp. 304-309